SCHEMBL21766091

SCHEMBL21766091

CCOc1cc(Cl)cc(S(=O)(=O)N2CCC(C(=O)NCc3ccc(Cl)cn3)CC2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 2/20 0.59
KMT2A Q03164 4/20 0.54
NPC1 O15118 1/20 0.53
RECQL P46063 1/20 0.52
PKM P14618 3/20 0.51
MEN1 O00255 3/20 0.51
GAA P10253 2/20 0.51
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
ALDH1A1 P00352 2/20 0.49
USP2 O75604 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
APOBEC3A P31941 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
EPHX2 P34913 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21766081 0.92 SLC13A5 (0.61) SLC13A5KMT2ANPC1RECQLPKM
SCHEMBL21766074 0.90 SLC13A5 (0.72) SLC13A5KMT2ARECQLPKMMEN1
SCHEMBL21765927 0.89 GAA (0.67) SLC13A5KMT2ANPC1RECQLPKM
SCHEMBL21766043 0.84 SLC13A5 (0.61) SLC13A5KMT2ARECQLPKMMEN1
SCHEMBL21766076 0.84 SLC13A5 (0.54) SLC13A5KMT2ANPC1RECQLPKM
SCHEMBL21766023 0.84 SLC13A5 (0.68) SLC13A5KMT2ANPC1RECQLPKM
SCHEMBL21765924 0.83 SLC13A5 (0.65) SLC13A5KMT2ARECQLPKMMEN1
SCHEMBL21765929 0.83 SLC13A5 (0.79) SLC13A5KMT2APKMLMNATP53
SCHEMBL21766069 0.82 SLC13A5 (0.65) SLC13A5KMT2ARECQLPKMMEN1
SCHEMBL20258760 0.82 SLC13A5 (0.73) SLC13A5KMT2ARECQLPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-10-06 US disclosed
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062708-A1 SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE CS, GLS, GLS2 SLC13A5 261/4885KMT2A 3613/4885NPC1 1089/4885
US-10793522-B2 Sulfonamides as inhibitors of the uptake of extracellular citrate CS, GLS, GLS2 SLC13A5 261/4885KMT2A 3613/4885NPC1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.